As of Tuesday, December 16, Champions Oncology, Inc.’s CSBR share price has dipped by 5.41%, which has investors questioning ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

CSBR runs a PDX bank. PDXs are mice models of human derived tumors. The company offers services to bio and pharma companies in pre clinical treatment testing. Its test have high predictive power for ...

Champions Oncology, Inc. (CSBR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

Q2 2026 Earnings Call Transcript December 15, 2025 Champions Oncology, Inc. misses on earnings expectations. Reported EPS is ...

For many, the main point of investing is to generate higher returns than the overall market. But every investor is virtually certain to have both over-performing and under-performing stocks. So we ...

Champions Oncology , Inc. (NASDAQ:CSBR) stock soared to a 52-week high, reaching $10.91, marking a significant milestone for the company specializing in advanced technology solutions and services to ...

We have seen 10 institutional investors add shares of $CSBR stock to their portfolio, and 8 decrease their positions in their most recent quarter.

Greetings. Welcome to the Champions Oncology First Quarter Fiscal Year 2025 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the ...

Champions Oncology Inc (CSBR) reports an 11% revenue increase and strategic investments in data platforms, despite challenges in the broader pharma market.